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Effect of the Immunosuppressant FK 506 on Insulin Release From 
Adult Rat Islets of Langerhans 
p.B. Carroll, AA Gongalves, A.C. Boschero, A.G. Tzakis, T.E. Starzl, and I. Atwater 
CLINICAL introduction of cyclosporine A (CyA) was 
a critical development that improved the success 
rate of organ transplantation. I Cy A has also been useful in 
the elucidation and treatment of type I diabetes as an 
autoimmune disease in animals2 and humans.) Despite the 
impressive achievements obtained with the use of CyA. 
nephrotoxicity has limited its use in an autoimmune dis· 
ease such as diabetes. Additionally. Cy A decreases insulin 
synthesis and secretion from several species4•7 and de-
creases insulin release from human islets in vitro.8 al-
though in vivo glucose tolerance and insulin dynamics may 
be normal in patients taking the drug.9 FK 506 is a new 
immunosuppressive agent that is more potent on a weight 
basis than Cy A 10 and has recently been used successfully 
in humans undergoing organ transplantations. II Since the 
drug has important potential applications in the fields of 
islet, whole pancreas transplantation. and immune inter-
vention for type I diabetes. we looked at the effects of FK 
506 on insulin secretion from adult rat islets of Langer-
hans. 
METHODS 
We used freshly isolated islets obtained by collagenase digestion 
of the pancreas from adult male Wistar rats.12 Insulin was mea-
sured by standard radioimmunoassay using a charcoal and dex-
tran separation method.1l After isolation, islets were washed live 
times in basal (2.8 mmollL glucose) containing buffer. 
We measured insulin released by basal (2.8 or 5.6 mmollL) or 
stimulatory (8.3 to 22 mmollL) glucose during a 9O-minute static 
incubation of groups of five freshly isolated islets incubated in the 
presence or absence of FK S06 (provided by Dr Raman Venka· 
tarmanan. University of Pittsburgh). Some studies were per· 
formed using CyA (kindly provided by Sandoz Research Institute. 
East Hanover. NJ). For all experiments a modified Krebs buffer 
was used that contained (in mmollL): 120 NaCI. S KCI, 2S 
NaHCO). 2.5 CaCI1• and LI MgC12• equilibrated with 95% 0.;% 
CO2, and supplemented with S mglmL bovine serum albumin. pH 
7.4. 31"C. 
Statistics 
ResuJts are expressed as mean :!: SEM. The statistical significance 
of insulin release data was analyzed by Student's t test. Data with 
multiple groups were analyzed using a one-way analysis of vari· 
ance (ANOY A) and the Wilcoxon ranked sums test. Conclusions 
drawn from parametric and non parametric analyses were the 
same. We used a stepwise multiple comparisons procedure to 
assess FK 506 dose-response results. 14 
RESULTS 
Figure 1 summarizes the effects of acute exposure of islets 
to various concentrations of either FK 506 or CyA on 
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Fig 1. Acute Effect of FK 506 on 16.7 mmoVL glucose-induced 
insulin release. In this and subsequent figures insulin release was 
me8SU'ed at the end of a 9O-minute incubation in all conditions. 
Values are expressed as the mean :t SEM (36 observations). In 
this and subsequent figures. 100% secretion corresponds to 
insulin measured in 16.7 mmollL glucose after subtraction of basal 
release. Basal insulin release (2.8 mmollL glucose-induced) was 
650 = 5.8 pglisl",tI9O min, and stimulated release (16.7 mM 
glucose induced) was 2200.8 ~ 20.9 pglisletl90 rm (P < .01). A 
concentration of 100 ng/mL FK 506 produced an average inhibition 
of 35% (P < .05). This concentration was inhbtory in every 
expennent. In one experiment. a concentration of 10 nglmL was 
also significantly inhibitory. Comparable data from islets incubated 
with CyA are shown in filled bars. Stimulated release was 1556.0 
:!: 102 pgflSlet!90 min (P < .01) and CyA (1 and 10 #'9/mL) 
produced a 30% inhibition of this release (P < .OS). 
glucose-induced insulin secretion. In all experiments 16.7 
mmollL glucose evoked a three to sevenfold rise in insulin 
secretion compared with basal (P < .01). The glucose-
stimulated insulin release was inhibited approximately 
359C by 100 ng/mL FK 506 (P < .05). This concentration 
was inhibitory in every experiment. 
In one experiment 10 ng/mL was also clearly inhibitory 
From the Laboratory of CeI Biology and Genetics, National 
Instilule of Diabetes DigestiYe and Kidney Diseases, National 
Instilutes of Health. Bethesda.. Maryland (P.B.C .• A.A.G., A.C.B .• 
LA.): and the Department of Surgery, University of Pittsburgh 
Mecic:al School, Pittsburgh, Pennsylvania (A.G.T •• T.E.S.). 
A.C.B. was supported by a grant from the Brazilian foundation 
CAPNS (Grant /I 1662189): AAG. was supported by CNPq, Sao 
Paolo. Brazil. 
Address reprint requests to P.B. Carroll, Bldg 8, Room 326. 
National Institutes of Health. Bethesda. MD 20892. 
C 1991 by Appleton & Lange 
Q041-13451911S3'()Ol +0 
Transplantation Proceedings, Vol 23. No 1 (February), 1991: pp 337-339 337 
338 
K~ loor A 
g 600 
" I 
.. 
.. 
'-. 400 
'" Q. 
! 
-' '00 
::> 
<It 
! 
''0 
100 B 
t' 
~ 10 
Z e 10 
a: 
~ '0 
III 
'0 
1.8 ~KI ._, 11.2 '6.7 22.2 
GLUCOSE (rr#.1) 
_. Ac::-506 
'00 ....... 
~ 2. Effect of FK 506 on basal insulin release (A) and glucose 
dose-response (8). Insulin release in 2.8 mmollL glucose was 
624.8 ± 53.0 pglisletl90 min in the control and 616.5 ± 58.3 
pglisletl90 min in FK 506-treated islets (n = 60 observations) (P = 
.92). Data in 8 were normalized to the basal and expressed as a 
percent of maximal secretion in each condition (n = 18 observa-
tions at each glucose concentration. three separate experiments). 
(P < .05). CyA at concentrations of I and 10 ~mi 
produced an approximately 30% inhibition of insulin re-
lease (P < .05). The effect of I ng/mL FK 506 was not 
additive with 1 or 10 i4¥mL CyA to further suppress 
insulin release (data not shown). 
Figure 2 illustrates the effects of acute exposure of the 
islets to 100 ng/mL FK 506 on basal-induced (2.8 mmol 
glucose) insulin release (Fig 2A) or the graded increase in 
insulin evoked by increasing glucose concentrations (Fig 
28). In this series of experiments. basal insulin release was 
624.8 ± 53 pg/isletJ90 min and, in the presence of FK 506. 
was 616.5 ± 58.3 pg/isletl9O min (P = .92). While FK 506 
did not inhibit insulin release at lower glucose concentra-
tions. it inhibited both 16_7 and 22 mmoVL glucose-
induced insulin release significantly (P < .005 and P < .03. 
respectively). In order to examine the effects of FK 506 on 
the 50% maximal and slope of the insulin response to 
glucose, the data points from Fig 28 were normalized to 
the maximum response within each condition and were 
fitted using the Boltzmann equation: % = PO)/(I + exp) 
{P(2) x ([G)-P(3)} where [G)-glucose concentration, P(2) = 
glucose sensitivity. P(3) = 50% maximal. and P(l) is the 
maximal stimulation in either condition. FK 506. while 
inhibiting the maximal secretion induced by high glucose 
concentrations (Fig 28), produced a small apparent shift in 
the glucose dose-response curve to the left from a 50% 
maximum of 10.6 mmoVL in the control to 9.8 mmoVL in 
the FK 506-treated islets. At the 50% maximum, the slope 
of glucose sensing was increased. 
DISCUSSION 
FK 506 is a potent new immunosuppressant agent. When 
used long-term 1M in baboons. FK 506 had an apparent 
diabetogenic effect. 15 When the immunosuppression was 
changed at 4 days to an oral regimen. this was not 
observed in baboons undergoing renal transplantation 16 
nor in cynomolgus monkeys undergoing pancreaticoduo-
denal allotransplantation. 17 Preliminary studies in human 
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Fig 3. Effect of FK 506 on the glucose dose-response slope and 
50% maximum insulin secretion. To examine the elTects of 100 
nglmL FK 506 on the slope of the glucose dose-response curve 
and the 50% maximum secretion, we fitted the data points from Fig 
28 using the Boltzmann equation (see text). The data were 
noonalized to the maximum values in eadl condition. FK 506 
produced a small shift in the 50% maximum along the x axis, the 
slope of glucose sensing was increased. 
recipients of liver allografts do not show a marked effect of 
this drug on carbohydrate tolerance when compared with 
historical controls who "ere treated "ith CyA_18 Thus far 
there have been few studies of the effect of this agent on 
islet cell function. FK 506 apparently does not alter 
morphology or interfere with insulin secretion from fetal 
islets of Langerhans. 19 Insulin secretion in neonatal and 
fetal islets is not comparable to the adult response,20.21 and 
since transplantation frequently involves tissue obtained 
from adult donors, we focused our studies on the effect of 
acute exposure to the drug on basal and glucose-stimulated 
insulin release. 
The present study shows that FK 506 does not inhibit 
basal insulin release. It does inhibit glucose-induced insu-
lin release at the highest concentrations used 00 and 100 
ng/mL). Our acute data are compatible with results that 
show a small inhibition after a 4-day culture of rat islets in 
the presence of FK 506. = These observations suggest that 
the inhibition is not cumulative at least during this time 
period. The amount of inhibition produced by FK 506 at 
high concentrations is similar to that produced by I and 10 
#'&"mL CyA. Our results with CyA are comparable to 
those reponed by others.6 
Of interest is the finding of an apparent shift in the 
glucose dose-response of insulin secretion in the presence 
of the drug. At lower glucose concentrations FK 506 does 
not inhibit insulin release and in fact some slight stimula-
tion of secretion is observed. The inhibitioo of release 
observed at 16.7 and 22 mmoVL glucose represents a shift 
of the normal dose-response of the islets to the left (Fig 3). 
The mechanism of such a shift is not clear from the current 
studies. One possible explanation would be that FK 506 
EFFECT OF FK 506 ON INSULIN RELEASE 
enhances calcium entry into the cells, which in high 
concentrations may be inhibitory in {3 cells as proposed by 
Draznin.23 These observations could have important clin-
ical correlates. 
In summary, our studies and those of others indicate 
that inhibition of insulin release is apparent only at high 
concentrations of FK 506 and glucose. FK 506 appears to 
have considerable steroid sparing effect. II Thus, there may 
be fewer problems with the diabetogenic effect of this 
agent except when used IV, in very high concentrations, or 
when there are preexisting problems of carbohydrate me-
tabolism. There are important species differences reported 
with side effects of this agent24 and further studies in 
humans are needed. Since there are potentially important 
applications of FK 506 in the field of diabetes, additional 
studies of effects of this agent on peripheral insulin action, 
glucose metabolism, response to non glucose secreta-
gogues, effect on other islet hormones, and molecular 
mechanism of action on secretory cells and target cells are 
required. 
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